A Phase 2 interventional study of LUM001 and Placebo in PBC and Primary Biliary Cirrhosis, sponsored by Mirum Pharmaceuticals, Inc.. Completed at 24 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-03-27.
Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Liver Cirrhosis, Biliary with a site in United States — 11 open to participants now, 18 under way, 8 of them phase 3. Liver Cirrhosis, Biliary · United States.
Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, this one is the 26th largest by enrollment of the 65 interventional ones that give a count, is one of 2 that started in 2013, is one of 34 in phase 2, and was the 22nd registered.
214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.
Browse Liver Cirrhosis, Biliary studies →11 of the 83 studies in Liver Cirrhosis, Biliary with a site in United States are open now. Recruiting first, the newest first:
Gilead Sciences · Sites in United States
Ages 18–75
Zydus Therapeutics Inc. · Sites in United States
Ages 18–80
Ipsen · Sites in United States
Women only
Zydus Therapeutics Inc. · Sites in United States
Ages 18+
Zydus Therapeutics Inc. · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 38 · Phase 3 18 · Phase 4 3
First in 1994; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is close to the median of 60 across 151 interventional studies indexed under Liver Cirrhosis, Biliary.
Median enrollment 46 across the 65 interventional studies, 430 across the 17 observational. Of the 61 that completed or were terminated, 33 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
56 of 83 have an industry lead sponsor. The 10 most frequent:
Mirum Pharmaceuticals, Inc. is the lead sponsor of 40 studies on the registry; 7 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 11 (92%) have results posted.
Mirum Pharmaceuticals, Inc. has 3 studies filed under Liver Cirrhosis, Biliary — fewer than ten, so there is no comparison to draw.
4 of the studies in Liver Cirrhosis, Biliary with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06427395Phase 3Zydus Therapeutics Inc.Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis | 2027-04-18 |
| NCT06825559Zydus Therapeutics Inc.Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease | 2026-12-31 |
| NCT05050136Mirum Pharmaceuticals, Inc.A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | 2027-01 |
| NCT07631442Stanford UniversityUsing Digital Health Technology to Monitor Patients With Primary Biliary Cholangitis (PBC) | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is a randomized, double-blind, placebo-controlled, multicenter study. It is a 13-week Phase 2 study in adults with primary biliary cirrhosis designed to compare the effect of daily dosing with UDCA in combination with LUM001 or placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered orally once daily
Drug: LUM001 · Drug: Ursodeoxycholic Acid
Administered orally once daily
Drug: Placebo · Drug: Ursodeoxycholic Acid
Also known as: UDCA
Change From Baseline in Pruritus Using Adult Itch Reported Outcome (ItchRO) Weekly Sum Score at Week 13/ Early Termination (ET)
Pruritus was assessed using ItchRO measure, administered as an electronic diary (eDiary) which was completed by the participants twice daily (morning and evening). (ItchRO) scores ranged from 0 to 10, with 0 representing no itch and 10 representing very severe itching. The highest score between the morning and evening ItchRO reports represented the daily score: a measure of the worst itching over the previous 24-hour period. The weekly sum score was calculated as the sum of the daily scores for the 7 days prior to the time point being reported: 7 days prior to randomization or 7 days prior to Week 13/ET visit.
Time frame: Baseline and Week 13/ET
Change From Baseline in Pruritus Using Adult ItchRO Weekly Sum Scores at Weeks 4, 8 and 13
ItchRO scores had a range from 0 to 10, with 0 representing no itch and 10 representing very severe itching. The highest score between the morning and evening ItchRO reports represented the daily score: a measure of the worst itching over the previous 24-hour period. The weekly sum score was calculated as the sum of the daily scores for the 7 days prior to the time point being reported: 7 days prior to randomization or 7 days prior to Week 13/ET visit.
Time frame: Baseline, Weeks 4, 8 and 13
Change From Baseline in Pruritus Using Adult ItchRO Average Daily Scores at Weeks 4, 8, 13, and Last Post-baseline Visit (Week 13/ET)
ItchRO scores had a range from 0 to 10, with 0 representing no itch and 10 representing very severe itching. The highest score between the morning and evening ItchRO reports represented the daily score: a measure of the worst itching over the previous 24-hour period. Adult ItchRO average daily score was the sum of daily scores divided by the number of days adult ItchRO was completed, using the 7 days prior to the reported visit date.
Time frame: Baseline, Weeks 4, 8, 13 and Last Post-baseline visit (Week 13/ET)
Change From Baseline in Alkaline Phosphatase (ALP) at Weeks 4, 8, 13, and Last Post-baseline Visit (Week 13/ET)
Laboratory serum ALP enzyme levels were evaluated using blood samples collected.
Time frame: Baseline, Weeks 4, 8, 13 and Last Post-baseline (Week 13/ET)
Change From Baseline in 5-D Itch Score at Weeks 4, 8, 13, and Last Post -Baseline Visit (Week 13/ET)
The 5-D itch (validated instrument to measure pruritus) scale was developed for the multidimensional quantification of pruritus that is sensitive to change over time. The 5-D itch scale included 5 domains (duration, degree, direction, disability, and distribution of pruritus). The total 5-D score was obtained by scoring each of the domains separately and then summing them together. 5-D total scores ranged between 5 (no pruritus) and 25 (most severe pruritus).
Time frame: Baseline, Weeks 4, 8, 13 and Last Post-baseline visit (Week 13/ET)
Change From Baseline in Fasting Serum Bile Acid Level at Weeks 4, 8, 13, and Last Post -Baseline Visit (Week 13/ET)
Laboratory serum bile acid level levels were evaluated using blood samples collected.
Time frame: Baseline, Weeks 4, 8, 13 and Last Post-baseline visit (Week 13/ET)
Change From Baseline in Bile Acid Synthesis as Measured by Serum 7 Alpha-Hydroxy-4-Cholesten-3-One C4 Level [7 Alpha C4]) at Weeks 4, 8, 13, and Last Post -Baseline Visit (Week 13/ET)
C4 7 alpha-hydroxy-4-cholesten-3-one is an intermediate in the biochemical synthesis of bile acids from cholesterol and its concentrations reflect the activity of the bile acid synthetic pathway. Elevated levels of C4 indicate bile acid malabsorption. Laboratory C4 levels were evaluated using blood samples collected.
Time frame: Baseline, Weeks 4, 8, 13 and Last Post-baseline Visit (Week 13/ET)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the product. A serious adverse event (SAE) was defined as an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly or birth defect; an important medical event that did not meet any of the above criteria but jeopardized the participant or required medical or surgical intervention to prevent one of the outcomes listed above. A TEAE was defined as any AE that occurred during the study, from the start of investigational product dosing through the end of the study (13 weeks of treatment period (or ET) + 14 days \]), or that worsened since the start of dosing.
Time frame: From the first dose of study drug until the 13 weeks of treatment period (or ET) + 14 days (approximately 15 weeks)
The study was conducted in 24 centers in the United Kingdom, Canada, and the United States between 19 August 2013 and 09 April 2015.
| Milestone | LUM001 10 mg + UDCA (Cohort A) | LUM001 20 mg + UDCA (Cohort B) | Placebo + UDCA (Cohort A) | Placebo + UDCA (Cohort B) |
|---|---|---|---|---|
| Started | 21 | 21 | 11 | 13 |
| Completed | 18 | 21 | 10 | 12 |
| Not completed | 3 | 0 | 1 | 1 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 |
Pruritus was assessed using ItchRO measure, administered as an electronic diary (eDiary) which was completed by the participants twice daily (morning and evening). (ItchRO) scores ranged from 0 to 10, with 0 representing no itch and 10 representing very severe itching. The highest score between the morning and evening ItchRO reports represented the daily score: a measure of the worst itching over the previous 24-hour period. The weekly sum score was calculated as the sum of the daily scores for the 7 days prior to the time point being reported: 7 days prior to randomization or 7 days prior to Week 13/ET visit.
| units on a scale | LUM001 10 mg + UDCA (Cohort A | LUM001 20 mg + UDCA (Cohort B) | Placebo + UDCA (Cohort A) | Placebo + UDCA (Cohort B) |
|---|---|---|---|---|
| Baseline | 48.11 ± 13.363 | 52.10 ± 13.780 | 54.64 ± 9.157 | 49.46 ± 14.110 |
| Change at Week 13/ET | -24.59 ± 15.240 | -27.67 ± 19.888 | -26.18 ± 18.313 | -22.77 ± 17.123 |
ItchRO scores had a range from 0 to 10, with 0 representing no itch and 10 representing very severe itching. The highest score between the morning and evening ItchRO reports represented the daily score: a measure of the worst itching over the previous 24-hour period. The weekly sum score was calculated as the sum of the daily scores for the 7 days prior to the time point being reported: 7 days prior to randomization or 7 days prior to Week 13/ET visit.
| units on a scale | LUM001 10 mg + UDCA (Cohort A) | LUM001 20 mg + UDCA (Cohort B) | Placebo + UDCA (Cohort A) | Placebo + UDCA (Cohort B) |
|---|---|---|---|---|
| Baseline (n=21, 21, 11, 13) | 48.11 ± 13.363 | 52.10 ± 13.780 | 54.64 ± 9.157 | 49.46 ± 14.110 |
| Change at Week 4 (n=20, 21, 11, 13) | -15.62 ± 13.708 | -22.19 ± 18.101 | -10.55 ± 11.103 | -16.23 ± 12.749 |
| Change at Week 8 (n=20, 21, 10, 13) | -21.92 ± 13.089 | -23.97 ± 20.398 | -23.50 ± 18.585 | -19.15 ± 15.302 |
| Change at Week 13 (n=18, 21, 10, 12) | -27.41 ± 14.346 | -27.67 ± 19.888 | -28.50 ± 17.520 | -22.92 ± 17.876 |
ItchRO scores had a range from 0 to 10, with 0 representing no itch and 10 representing very severe itching. The highest score between the morning and evening ItchRO reports represented the daily score: a measure of the worst itching over the previous 24-hour period. Adult ItchRO average daily score was the sum of daily scores divided by the number of days adult ItchRO was completed, using the 7 days prior to the reported visit date.
| units on a scale | LUM001 10 mg + UDCA (Cohort A) | LUM001 20 mg + UDCA (Cohort B) | Placebo + UDCA (Cohort A) | Placebo + UDCA (Cohort B) |
|---|---|---|---|---|
| Baseline (n=21, 21, 11, 13) | 6.873 ± 1.9091 | 7.442 ± 1.9686 | 7.805 ± 1.3082 | 7.066 ± 2.0158 |
| Change at Week 4 (n=20, 21, 11, 13 | -2.231 ± 1.9587 | -3.170 ± 2.5859 | -1.506 ± 1.5861 | -2.319 ± 1.8212 |
| Change at Week 8 (n=20, 21, 10, 13) | -3.131 ± 1.8703 | -3.424 ± 2.9139 | -3.357 ± 2.6549 | -2.736 ± 2.1860 |
| Change at Week 13 (n=18, 21, 10, 12) | -3.915 ± 2.0496 | -3.952 ± 2.8411 | -4.071 ± 2.5028 | -3.274 ± 2.5537 |
| Change at Week 13/ET (n=21, 21, 11, 13) | -3.512 ± 2.1774 | -3.952 ± 2.8411 | -3.740 ± 2.6161 | -3.253 ± 2.4461 |
Laboratory serum ALP enzyme levels were evaluated using blood samples collected.
| units per liter (U/L) | LUM001 10 mg + UDCA (Cohort A) | LUM001 20 mg + UDCA (Cohort B) | Placebo + UDCA (Cohort A) | Placebo + UDCA (Cohort B) |
|---|---|---|---|---|
| Baseline (n=21, 21, 11, 13) | 288.2 ± 193.91 | 257.6 ± 190.38 | 253.9 ± 96.83 | 274.2 ± 190.85 |
| Change at Week 4 (n=20, 21, 10, 13) | -22.1 ± 54.94 | 13.2 ± 47.76 | 20.3 ± 49.68 | -0.7 ± 39.69 |
| Change at Week 8 (n=20, 21, 10, 12 | 2.6 ± 53.95 | 1.1 ± 41.98 | 8.8 ± 38.72 | -4.8 ± 55.70 |
| Change at Week 13 (n=17, 20, 10, 12) | -15.2 ± 97.19 | 18.5 ± 56.21 | 24.3 ± 76.48 | -7.2 ± 83.70 |
| Change at Week 13/ET (n=21, 21, 11, 13) | -8.0 ± 93.02 | 16.4 ± 55.60 | 22.9 ± 72.70 | -7.9 ± 80.19 |
The 5-D itch (validated instrument to measure pruritus) scale was developed for the multidimensional quantification of pruritus that is sensitive to change over time. The 5-D itch scale included 5 domains (duration, degree, direction, disability, and distribution of pruritus). The total 5-D score was obtained by scoring each of the domains separately and then summing them together. 5-D total scores ranged between 5 (no pruritus) and 25 (most severe pruritus).
| units on a scale | LUM001 10 mg + UDCA (Cohort A) | LUM001 20 mg + UDCA (Cohort B) | Placebo + UDCA (Cohort A) | Placebo + UDCA (Cohort B |
|---|---|---|---|---|
| Baseline (n=21, 21, 11, 13) | 18.7 ± 3.47 | 19.4 ± 3.49 | 19.6 ± 2.94 | 19.2 ± 3.32 |
| Change at Week 4 (n=20, 21, 10, 13) | -4.8 ± 3.91 | -6.3 ± 4.96 | -3.4 ± 3.89 | -4.2 ± 3.81 |
| Change at Week 8 (n=20, 21, 10, 12) | -6.8 ± 3.16 | -5.9 ± 5.62 | -6.4 ± 6.20 | -4.4 ± 4.27 |
| Change at Week 13 (n=18, 21, 10, 12) | -7.4 ± 3.68 | -7.0 ± 5.89 | -7.8 ± 5.94 | -6.1 ± 4.68 |
| Change at Week 13/ET (n=21, 21, 10, 13) | -6.5 ± 4.11 | -7.0 ± 5.89 | -7.8 ± 5.94 | -5.6 ± 4.79 |
Laboratory serum bile acid level levels were evaluated using blood samples collected.
| micromoles per liter | LUM001 10 mg + UDCA (Cohort A) | LUM001 20 mg + UDCA (Cohort B) | Placebo + UDCA (Cohort A) | Placebo + UDCA (Cohort B) |
|---|---|---|---|---|
| Baseline (n=21, 21, 11, 13) | 33.110 ± 30.5943 | 52.460 ± 94.3892 | 52.615 ± 64.6162 | 58.434 ± 73.9895 |
| Change at Week 4 (n=20, 21, 10, 13) | -11.204 ± 31.6132 | -14.465 ± 58.5891 | -10.221 ± 50.0398 | 14.317 ± 75.1092 |
| Change at Week 8 (n=20, 21, 10, 12) | -3.968 ± 45.7388 | -21.983 ± 78.6134 | -3.585 ± 52.4398 | 34.893 ± 67.7189 |
| Change at Week 13 (n=18, 21, 10, 12) | -8.122 ± 48.1290 | -19.098 ± 81.8452 | 11.481 ± 44.0465 | 4.123 ± 46.2170 |
| Change at Week 13/ET (n=21, 21, 10, 13) | -4.504 ± 45.7595 | -19.098 ± 81.8452 | 11.481 ± 44.0465 | 3.690 ± 44.2770 |
C4 7 alpha-hydroxy-4-cholesten-3-one is an intermediate in the biochemical synthesis of bile acids from cholesterol and its concentrations reflect the activity of the bile acid synthetic pathway. Elevated levels of C4 indicate bile acid malabsorption. Laboratory C4 levels were evaluated using blood samples collected.
| nanogram per milliliter (ng/mL) | LUM001 10 mg + UDCA (Cohort A) | LUM001 20 mg + UDCA (Cohort B) | Placebo + UDCA (Cohort A) | Placebo + UDCA (Cohort B) |
|---|---|---|---|---|
| Baseline (n=21, 21, 10, 13) | 18.74 ± 16.180 | 13.17 ± 11.851 | 22.31 ± 20.769 | 16.98 ± 33.093 |
| Change at Week 4 (n=20, 21, 9, 13) | 8.66 ± 23.422 | 17.03 ± 18.380 | -6.80 ± 6.783 | -0.19 ± 8.856 |
| Change at Week 8 (n=20, 21, 9, 12) | 13.04 ± 17.895 | 15.03 ± 31.120 | -12.57 ± 14.630 | 3.43 ± 16.666 |
| Change at Week 13 (n=18, 21, 9, 12) | 24.38 ± 38.105 | 6.62 ± 10.116 | -12.72 ± 10.374 | 4.56 ± 13.610 |
| Change at Week 13/ET (n=21, 21, 9, 13) | 20.56 ± 37.312 | 6.62 ± 10.116 | -12.72 ± 10.374 | 4.74 ± 13.047 |
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the product. A serious adverse event (SAE) was defined as an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening; persistent or significant disability/incapacity; congenital anomaly or birth defect; an important medical event that did not meet any of the above criteria but jeopardized the participant or required medical or surgical intervention to prevent one of the outcomes listed above. A TEAE was defined as any AE that occurred during the study, from the start of investigational product dosing through the end of the study (13 weeks of treatment period (or ET) + 14 days \]), or that worsened since the start of dosing.
| participants | LUM001 5 mg + UDCA | LUM001 10 mg + UDCA | LUM001 20 mg + UDCA | Placebo + UDCA |
|---|---|---|---|---|
| TEAEs | 1 | 19 | 21 | 17 |
| TESAEs | 0 | 2 | 1 | 0 |
Collected over From the first dose of study drug until the 13 weeks of treatment period (or ET) + 14 days (approximately 15 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LUM001 5 mg + UDCA | — | 0/1 (0%) | 1/1 (100%) |
| LUM001 10 mg + UDCA | — | 2/20 (10%) | 18/20 (90%) |
| LUM001 20 mg + UDCA | — | 1/21 (4.8%) | 20/21 (95.2%) |
| Placebo + UDCA | — | 0/24 (0%) | 16/24 (66.7%) |
| Event | LUM001 5 mg + UDCA | LUM001 10 mg + UDCA | LUM001 20 mg + UDCA | Placebo + UDCA |
|---|---|---|---|---|
| Myocardial InfarctionCardiac disorders | 0/1 | 1/20 | 0/21 | 0/24 |
| Abdominal PainGastrointestinal disorders | 0/1 | 1/20 | 0/21 | 0/24 |
| Gastrointestinal HaemorrhageGastrointestinal disorders | 0/1 | 0/20 | 1/21 | 0/24 |
| Event | LUM001 5 mg + UDCA | LUM001 10 mg + UDCA | LUM001 20 mg + UDCA | Placebo + UDCA |
|---|---|---|---|---|
| Abdominal PainGastrointestinal disorders | 1/1 | 4/20 | 5/21 | 1/24 |
| DiarrhoeaGastrointestinal disorders | 1/1 | 14/20 | 11/21 | 6/24 |
| NauseaGastrointestinal disorders | 1/1 | 5/20 | 4/21 | 4/24 |
| DizzinessNervous system disorders | 1/1 | 0/20 | 1/21 | 1/24 |
| VomitingGastrointestinal disorders | 1/1 | 0/20 | 1/21 | 2/24 |
| HeadacheNervous system disorders | 0/1 | 3/20 | 2/21 | 8/24 |
| Abdominal Pain UpperGastrointestinal disorders | 0/1 | 4/20 | 6/21 | 2/24 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/1 | 4/20 | 1/21 | 0/24 |
| Abdominal DistensionGastrointestinal disorders | 0/1 | 3/20 | 0/21 | 3/24 |
| Pain In ExtremityMusculoskeletal and connective tissue disorders | 0/1 | 0/20 | 3/21 | 0/24 |
| Age, Continuous(years) | LUM001 10 mg + UDCA (Cohort A) | LUM001 20 mg + UDCA (Cohort B) | Placebo + UDCA (Cohort A) | Placebo + UDCA (Cohort B) | Total |
|---|---|---|---|---|---|
| Mean | 54.7 ± 12.74 | 53.5 ± 10.53 | 47.5 ± 8.14 | 55.8 ± 8.73 | 53.3 ± 10.77 |
| Sex: Female, Male(Participants) | LUM001 10 mg + UDCA (Cohort A) | LUM001 20 mg + UDCA (Cohort B) | Placebo + UDCA (Cohort A) | Placebo + UDCA (Cohort B) | Total |
|---|---|---|---|---|---|
| Female | 20 | 17 | 11 | 12 | 60 |
| Male | 1 | 4 | 0 | 1 | 6 |
The record gives a start of Aug 2013, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2016, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maralixibat